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Voltage-gated Ca2 channels in arterial myocytes canmediate Ca2
release from the sarcoplasmic reticulum and, thus, induce contrac-
tion without the need of extracellular Ca2 influx. This metabo-
tropic action of Ca2 channels (denoted as calcium-channel-
induced calcium release or CCICR) involves activation of G proteins
and the phospholipase C-inositol 1,4,5-trisphosphate pathway.
Here, we show a form of vascular tone regulation by extracellular
ATP that depends on the modulation of CCICR. In isolated arterial
myocytes, ATP produced facilitation of Ca2-channel activation
and, subsequently, a strong potentiation of CCICR. The facilitation
of L-type channel still occurred after full blockade of purinergic
receptors and inhibition of G proteinswith GDPS, thus suggesting
that ATP directly interacts with Ca2 channels. The effects of ATP
appear to be highly selective, because they were not mimicked by
other nucleotides (ADP or UTP) or vasoactive agents, such as
norepinephrine, acetylcholine, or endothelin-1. We have also
shown that CCICR can trigger arterial cerebral vasoconstriction in
the absence of extracellular calcium and that this phenomenon is
greatly facilitated by extracellular ATP. Although, at low concen-
trations, ATP does not induce arterial contraction per se, this agent
markedly potentiates contractility of partially depolarized or
primed arteries. Hence, the metabotropic action of L-type Ca2
channels could have a high impact on vascular pathophysiology,
because, even in the absence of Ca2 channel opening, it might
mediate elevations of cytosolic Ca2 and contraction in partially
depolarized vascular smooth muscle cells exposed to small con-
centrations of agonists.
L-type Ca2 channel  vascular contractility  excitation–contraction
coupling
Contraction of vascular smooth muscle cells (VSMCs) deter-mines vessel diameter and, thus, regulates blood flow and
pressure. VSMC contraction is triggered by a rise of cytosolic
calcium ion concentration ([Ca2]) due to either transmembrane
Ca2 influx or Ca2 release from the sarcoplasmic reticulum (SR).
Extracellular Ca2 entry normally occurs through L-type voltage-
dependent Ca2 channels, although there are numerous ligand-
gated membrane channels that are also Ca2 permeable (1). Ca2
release from the SR is mediated by inositol trisphosphate (InsP3)
and ryanodine receptors. Vasoactive agents acting on the different
vascular territories induce VSMC contraction by binding to mem-
brane receptors and the subsequent activation of one or more of the
Ca2-entry andor Ca2-release channels (2–5).
We have described a previously unnoticed metabotropic effect of
vascular L-type Ca2 channels, denoted as calcium-channel-
induced Ca2 release (CCICR), which requires Ca2 channel
activation but is independent of extracellular Ca2 influx (6). This
new Ca2-release mechanism depends on the conformational
change of L-type Ca2 channels and the downstream activation of
the G proteinphospholipase C (PLC) cascade, leading to synthesis
of InsP3 and Ca2 release from the SR (6, 7). Although CCICR can
be triggered either by direct membrane depolarization in patch-
clamped myocytes or upon exposure of the cells to a high-K
solution (6), its actual physiological significance is unknown. This
research was undertaken to study the possible synergistic interac-
tion between CCICR and vasoactive agents and to evaluate the
impact of CCICR on arterial contractility. It had been reported in
several cell types (including arterial myocytes) that agonist-induced
Ca2 release from internal stores can be modulated by the cell’s
membrane potential. However, this phenomenon was not associ-
ated with L-type Ca2 channel activation but was attributed to the
existence of a voltage-dependent step in the PLC-activationInsP3-
synthesis pathway (8–10). Here, we report that CCICR is, indeed,
selectively regulated by low concentrations of extracellular ATP, an
agent coreleased with norepinephrine (NE) from sympathetic
terminals and from cells (erythrocytes and platelets) damaged
during vascular injury (11–13). Moreover, CCICR can produce
arterial cerebral vasoconstriction in the absence of extracellular
Ca2 influx, and this effect is greatly potentiated by subthreshold
concentrations of ATP. Unexpectedly, ATP directly modifies L-
type Ca2 channel gating and, thus, increases both Ca2-current
amplitude and CCICR. This metabotropic action of L-type Ca2
channels could be of high relevance for vascular pathophysiology
because, even in the absence of Ca2 channel opening, it might
mediate elevations of cytosolic Ca2 and protracted contraction in
partially depolarized VSMCs exposed to small concentrations of
agonists.
Results
Extracellular ATP Potentiates Ca2 Channel-Induced Ca2 Release.
Voltage-gated Ca2 channels of VSMCs in the different vascular
territories can be regulated by numerous vasomotor agents (2,
14–17); hence, we sought synergistic interactions between some of
these agents and CCICR. In voltage-clamped myocytes bathed in
Ca2-free medium that responded to step membrane depolariza-
tion with only a small increase or no change of cytosolic [Ca2], the
presence of extracellular ATP resulted in a marked augmentation
of CCICR amplitude (Fig. 1A Left). Cells selected for these
experiments were either unresponsive to ATP (10–100 M) or
showed only a minor Ca2 response to the nucleotide at the holding
potential of 70 mV. Application in the same cells of NE or
acetylcholine (ACh), agents without vasoconstrictive action on the
basilar artery (18, 19), failed to produce any effect on CCICR (n
9) (Fig. 1ARight). Both the depolarization-induced Ca2 signal and
its potentiation by extracellular ATP disappeared when the SR
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Ca2 store was depleted by the addition of caffeine (Fig. 1B).
Blockade of the G proteinPLC cascade with intracellular GDPS
(1 mM), which completely suppresses CCICR (6), also abolished
the potentiation by ATP (n 4 cells tested). CCICR signals evoked
by step depolarizations appeared with a latency of several seconds,
probably reflecting the time required to synthesize sufficient InsP3
to release Ca2 from the SR (Fig. 1C). This latency (measured as
the time to reach the peak of the Ca2 signal) was voltage-
dependent and varied from 15.9  2 s (n  7) for small depolar-
izations (from 70 mV to membrane voltages between 30 and
10 mV) to 8.5 1 s, (n 12) for larger depolarizations (from70
mV to potentials between30 and50 mV) (P 0.05). Exposure
to ATP significantly reduced the duration of the latency and
increased the amplitude of the Ca2 spike (Fig. 1D), thus further
suggesting potentiation of CCICR by ATP.
Because, in the absence of membrane depolarization, CCICR
can be triggered by pharmacological activation of Ca2 channels
with 2,5-dimethyl-4-[2-(phenylmethyl)benzoil]-1H-pyrrole-3-
carboxylic acid methyl ester (FPL)-64176, a well known Ca2
channel agonist (20–22), we tested to see the interaction between
FPL and ATP. In intact cells where FPL or ATP alone evoked only
small Ca2 signals, simultaneous exposure to both agents markedly
increased the amplitude of the Ca2 spikes independently of their
order of application (Fig. 2 A–C). Therefore, these data indicate
that ATP potentiates CCICR evoked by either step membrane
depolarization or FPL.
Direct and Selective Activation of L-Type Ca2 Channels by ATP in
Arterial Myocytes. Because CCICR requires Ca2 channel activa-
tion, we investigated the effect of ATP on the macroscopic voltage-
dependent Ca2 currents recorded in patch-clamped myocytes.
These currents were unaffected by NE (10 M, n 7) (Fig. 3A) or
ACh (10 M, n 6), agents that, as shown above (see Fig. 1A), did
not influence the CCICR signals (Table 1). However, in the same
cells, ATP (10M) elicited an increase in the amplitude of the Ca2
currents of 30–40% in the entire range of membrane potentials
(Fig. 3 A and B). At 20 mV, the peak Ca2 current increased
significantly in the presence of ATP and was almost completely
blocked by nifedipine (Table 1). Besides the increase in the Ca2
conductance, ATP accelerated activation and slowed inactivation
and closing kinetics (see Fig. 5, which is published as supporting
information on the PNAS web site). To further evaluate the
specificity of the effect of ATP on rat basilar myocytes, we tested
the action of endothelin-1 (ET-1), an efficacious constrictor in the
Fig. 1. Potentiation of Ca2 channel-induced Ca2 release
(CCICR) by extracellular ATP. (A Left) Ca2 release evoked by
the application of depolarizing pulses from 70 mV to 40
mV in a voltage-clamped myocyte bathed in Ca2-free solu-
tion. The amplitude of the Ca2 signal increased in the pres-
ence of ATP (10M). (ARight) Lack of effect of NE (10M) and
ACh (10 M) on Ca2 release. (B) Abolishment of CCICR after
the intracellular reservoirs are depleted by addition of caf-
feine (5 mM). The fluorimetric Ca2 signals are accompanied
by the corresponding membrane voltage (Vm, mV) and hold-
ing current (Im, pA) recordings. (C) Ca2 signal in response to
a depolarizing pulse shown at an expanded time scale to
illustrate the delay (latency) between the change in the mem-
brane potential and the maximum value of the increase in the
cytosolic [Ca2]. (D) Effect of ATP on the latency (open bars)
and amplitude (filled bars, arbitrary units) of depolarization-
induced Ca2 spikes. *, P  0.05. External solution: nominal
0Ca2 plus 2 mM EGTA added. The number of cells studied is
indicated in parentheses. a.u., arbitrary units; caf, caffeine.
Fig. 2. Synergistic interaction of extracellular ATP and FPL-
induced CCICR. (AandB) Measurement of Ca2 release evoked
by the exposure to FPL (2.5 M) andor ATP (25 M). The
amplitude of Ca2 spikes markedly increased when both ago-
nists were present simultaneously. (C) Summary of the effects
of ATP and FPL on cytosolic [Ca2] in undialyzed myocytes in a
0Ca solution containing 2 mM EGTA. The number of cells
studied is indicated in parentheses.
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basilar artery (23, 24). ET-1 had no significant effect on the
amplitude of the macroscopic Ca2 current (Fig. 3C). Peak Ca2
current amplitude recorded during depolarizations to 20 mV
before and after application of ET-1 (5–10 nM) were 99.6  16.9
pA and 98.8  19.8 pA, respectively (n  5). In these same cells,
current amplitude significantly increased in the presence of ATP
(10 M; 170.9 26.9 pA). To distinguish between a possible direct
effect of ATP on Ca2 channels and the indirect modulation
mediated by activation of metabotropic P2Y receptors, we per-
formed experiments using the ATP-receptor antagonist suramin
(25 M). This concentration was sufficient to block 93 5% of the
Ca2-release signal in intact cells (n  22), where ATP (10 M)
produced a large Ca2 transient. Nevertheless, suramin neither had
an effect on the amplitude of the Ca2 current nor prevented the
increase of current amplitude induced by ATP (Fig. 3D and Table
1). Moreover, simultaneous addition of suramin and pyridoxal
phosphate 6-azophenyl-2,4-disulfonic acid (another P2 antago-
nist) (17) yielded similar results (see Fig. 6A, which is published as
supporting information on the PNAS web site). The reversible
augmentation of Ca2 current amplitude by ATP occurred in cells
dialyzed with 1 mM GDPS (Fig. 3E, Table 1) and was not
mimicked by either other adenine nucleotides (ADP) or the P2Y
receptor agonist UTP (Fig. 3F, Table 1). However, the nonhy-
droxylable analogue ATPS produced a current potentiation sim-
ilar to ATP (see Fig. 6B). As expected, ATP markedly enhanced the
FPL-induced activation of Ca2 channels (Fig. 3 G and H). These
data strongly suggest that, in basilar myocytes, ATP enhances Ca2
current amplitude through direct interaction with the channels, thus
explaining the potentiation of CCICR described in the preceding
section. This effect of ATP on vascular L-type Ca2 channels does
not seem to be restricted to basilar myocytes, because it was also
observed with similar characteristics (40% increase of peak
Ca2-current amplitude at 20 mV, n  5) in experiments per-
formed on dispersed pulmonary artery myocytes.
Extracellular ATP Potentiates Contraction Induced by CCICR in Intact
Arterial Rings. Because CCICR can induce contraction in isolated
basilar myocytes (6), we studied whether the metabotropic activa-
tion of Ca2 channels can, indeed, produce contraction in intact
arterial rings and whether ATP can modulate the CCICR-
dependent vasomotor responses. Exposure of basilar arterial rings
to a depolarizing solution with 70 mM K produced a powerful and
reversible contractive response (7.02 0.37 mN, n 8). Although
it is generally thought that much of the K-induced contractility
depends on extracellular Ca2 influx, it is noteworthy that the
response to high Kwas not completely abolished by using external
solutions without Ca2 plus 0.2–0.5 mM EGTA (0Ca solution). In
these conditions, depolarization with 70 mM K produced an
appreciable vasoconstriction of 13 the amplitude of that pro-
duced with normal extracellular [Ca2] (2.4 0.5 mN, n 9) (Fig.
4A). To ascertain what signal (either membrane depolarization per
se or Ca2 channel activation) triggers SR Ca2 release and
contraction of basilar arterial rings, we performed experiments with
FPL. Pharmacological activation of Ca2 channels with FPL elic-
ited a powerful contraction of arterial rings (7.01 1.9 mN, n 21),
which was partially preserved (2.85  0.38 mN, n  23) after
removal of extracellular Ca2 (Fig. 4B). Interestingly, the FPL-
induced arterial contraction almost disappeared (95% inhibition,
n  5) in the presence of U73122 (1–5 M), a selective blocker of
PLC (25) without effects on Ca2 currents (Fig. 4C). The isoform
U73433, inactive on the enzyme, did not alter the FPL-dependent
contraction. These observations indicate that, in the absence of
extracellular Ca2 influx, FPL can produce vasoconstriction due to
Ca2 release from internal stores. Because FPL activates Ca2
channels without primarily altering the membrane potential, the
data strongly suggest that it is Ca2 channel activation, independent
of any change in membrane voltage, that induces Ca2 release and
vasoconstriction.
Given that a significant fraction of L-type Ca2 channel-
dependent contraction in arterial myocytes seems to be mediated
through CCICR, we investigated, in arterial rings, the interaction
between ATP and CCICR described in isolated myocytes. First, we
analyzed the contractive responses of arterial rings exposed to low
concentrations of ATP (1–10 M) and 40 mM K. It was tested
before that, with this concentration of extracellular K, the mem-
brane potential of isolated patch-clamped myocytes was depolar-
ized to 25.4  5.2 mV (n  5) and that, at high concentrations,
ATP contracted arterial rings (2.9 1.6 mN; n 47). Although low
Fig. 3. Activation of Ca2 channels by ATP in voltage-clamped myocytes. (A)
Increase in Ca2 current by external application of ATP (10 M) and lack of
effect of NE (10 M). (B) Current amplitude (measured at the end of depo-
larizing pulses) as a function of the membrane potential (Vm) in control
myocytes (open symbols) and after exposure to ATP for 2–4 min (filled
symbols). Each point is the mean SE of measurements done in five myocytes.
(C) Increase in Ca2 current by external application of ATP (10 M) and lack of
effect of endothelin-1 (10 nM). In most experiments, NE and endothelin-1
were applied for at least 3 min. (D) Increase of Ca2-current amplitude by ATP
in the presence of suramin (25 M). The Ca2 current was unaffected by
suramin but was almost completely abolished by nifedipine (1 M). (E) Re-
versible potentiation of Ca2 current by ATP in myocytes internally dialyzed by
GDPS (1 mM) to block G protein. (F) The effect of ATP on Ca2 current is not
mimicked by the P2-receptor agonist UTP (10 M). (G) ATP (10 M) markedly
enhanced the effect of FPL (50 nM) on Ca2 currents in patch-clamped myo-
cytes. All current traces were obtained by depolarization to20 mV from70
mV. (H) Summary of ATP and FPL effects on Ca2-current amplitude. *, P 
0.05. The number of cells studied is indicated in parentheses.
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concentrations of ATP (1 M) generally failed to evoke any
arterial-ring contraction, the isometric force induced by 40 K
(3.3 0.5 mN) was significantly increased (4.9 0.56 mN, n 15)
in the presence of ATP, even after purinergic-receptor blockade
with suramin (Fig. 4D). Note that there was no statistically signif-
icant difference between the contraction induced by 40 K in the
presence and absence of suramin. These experiments on arterial
rings indicate that, in fair agreement with the data in single cells,
isometric force elicited by 40 K-induced depolarization is mark-
edly potentiated by small concentrations of ATP, below those
required to evoke vasoconstriction.
Because ATP can enhance the FPL-dependent potentiation of
both Ca2 currents and Ca2 release in isolated myocytes (see Figs.
2 and 3), we also analyzed the interaction between these agents
using arterial rings. In the absence of extracellular Ca2, ATP
reversibly increased the vasoconstriction induced by FPL (Fig. 4E).
This additive effect of FPL and ATP was observed even with
concentrations of the two agents below those required to induce a
contractive response separately. In contrast, vasoconstriction in-
duced by FPL was not potentiated by the simultaneous addition of
small concentrations of ET-1 (data not shown), which is compatible
with the lack of effect of ET-1 on the macroscopic Ca2 current in
basilar myocytes (see Fig. 3C). Because FPL induced Ca2 release
in the absence of membrane depolarization (6), these data further
support the view that ATP can potentiate FPL-induced CCICR
and, thus, arterial ring contraction without the need of large
changes in membrane voltage.
Discussion
The main observations in this study are: (i) CCICR is markedly
and selectively increased by extracellular ATP; (ii) the effect of
ATP is mediated through the direct activation of Ca2 channels,
leading to Ca2 release from the SR and vasoconstriction; (iii)
CCICR, a phenomenon studied before in isolated arterial myo-
cytes (6), can elicit contraction in arterial basilar rings in the
absence of extracellular Ca2 and is potentiated by ATP; and (iv)
the interaction among ATP, membrane depolarization, and
CCICR represents a new form of eliciting arterial-myocyte
contraction, even in the absence of Ca2 channel opening, which
could contribute to pathophysiological conditions presenting
persistent vasoconstriction.
We have shown that CCICR, indeed, has physiological signifi-
cance, because it is differentially modulated by vasoactive agents.
NE is known to increase the open probability of Ca2 channels in
mesenteric myocytes (14) and increased Ca2 currents in rabbit ear
artery (15). However, the effect of NE varies in different vascular
territories, because we have observed that NE (up to 10 M) does
not influence the contractility of the basilar arterial rings and the
absence effect of this drug on the basilar artery studied in vivo has
been reported (26). In accord with these results, we have also shown
that NE has no effect on Ca2currents in basilar myocytes and,
therefore, does not modulate CCICR. ACh, a vasoactive agent in
some vascular territories (27, 28), and ET-1, an efficacious con-
strictor in the rat basilar artery (24), also failed to induce potenti-
ation of CCICR or Ca2 currents in our preparation. In contrast,
ATP, a vasoactive agent in the mammalian cerebral circulation (12,
13, 29), exerts a powerful facilitatory role on CCICR and rat basilar
myocyte contractility. ATP is known to elicit, in VSMCs, either
Ca2 influx through ligand-gated calcium channels or Ca2 release
due to activation of metabotropic P2Y receptors (3, 30). These
effects of ATP are abolished by blockade of the receptors with
suramin or pyridoxal phosphate 6-azophenyl-2,4,-disulfonic acid,
in the case of effects mediated by P2Y receptors, or after G protein
inhibition by the intracellular application of GDPS. Interestingly,
we describe here that, after blockade of purinergic receptors, ATP
(even at subthreshold concentration) reversibly increases Ca2-
current amplitude and, in the absence of extracellular Ca2, en-
hances CCICR and, subsequently, arterial contractility. These
phenomena appear to be highly selective, because other nucleotides
(ADP or UTP) or the vasoactive agents tested (NE, ACh, or ET-1)
did not produce the same effect as ATP. ATP and FPL had an
additive effect on myocyte Ca2 channels, thus suggesting that they
act through separate mechanisms to increase the macroscopic
current amplitude. ATP’s effects on Ca2 channels were unaltered
by intracellular dialysis with GDPS but were mimicked by extra-
cellular ATPS. Altogether, these data strongly suggest that ATP
directly interacts with a receptor site in the channel molecule to
favor Ca2 channel activation. A qualitatively similar phenomenon
has been observed in ventricular myocytes, where direct interaction
of ATP with the channels was suggested, because the effect was
maintained in single L-type Ca2 channels reconstituted into planar
lipid bilayers (31, 32). Therefore, two observations in our study are
the direct and selective facilitatory effect of ATP on L-type
Ca2currents in vascular myocytes and, more significantly, the
potentiation of CCICR by ATP. CCICR is inhibited by nifedipine
and other Ca2 antagonists (6), thus explaining why ATP-induced
Ca2 release in basilar myocytes is abolished after application of
these drugs (3).
Besides the effect of ATP on myocyte Ca2 channels, we have
demonstrated that, without extracellular Ca2 influx, basilar arte-
rial smooth muscle can contract in response to Ca2 channel
activation by either membrane depolarization or direct pharmaco-
Table 1. Regulation of L-type Ca2-channel activity by vasoactive agents
Internal Cs solution Control
ACh
(10 M)
NE
(10 M)
ATP
(10 M)
Suramin
(25 M)
ATP 
suramin
ATP  nifed
(1 M)
UTP
(10 M)
ADP
(10 M)
Control 141  23 184  22* 29.8  4.7*
n  12
Control 107.5  15.3 104.7  14.4 131  19*
n  9
Control  GDPS 177.1  26 235.9  30*
n  13
Control  GDPS 184.6  35.7 181  36
n  6
Control  GDPS 123.86  45 126.69  44.7
n  7
Control  GDPS 87  11.2 94.36  12.3 139.3  14*
n  6
Control  GDPS 107.13  13.3 103.36  14.4 141.4  13.4*
n  7
The data show the effect of ACh, NE, ATP, UTP, ADP, nifedipine, and suramin (added to the external solution; concentrations are in parentheses) and GDPS
(1 mM; added to the internal solution) on macroscopic Ca2 currents (expressed in pA as mean SE). Experiments were done in voltage-clamped myocytes, and
current was measured at the end of the depolarizing pulses to20 mV from a holding potential of70 mV. Asterisks indicate statistically significant differences
with respect to the values obtained with control solutions. nifed, nifedipine.
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logical modulation. These results agree with previous studies in
intestine (33), aorta (34), coronary artery (35), human umbilical
artery (36), and portal vein (37), in which contraction of smooth
muscle cells by a Ca2-free depolarizing solution was reported.
Contraction of the basilar artery elicited upon Ca2 channel
activation does not necessarily require membrane depolarization,
because FPL, a Ca2 channel agonist that directly modifies Ca2
channel gating, (20–22) also produced contraction of arterial rings
bathed in Ca2-free solution. These findings are in excellent
agreement with the data obtained in single myocytes, demonstrat-
ing that CCICR (the coupling of Ca2 channels to the SR through
the activation of the PLCInsP3 pathway) can be triggered by either
membrane depolarization or FPL. The CCICR helps to explain the
dependence of InsP3-dependent Ca2 release on the membrane
potential observed in smooth muscle (8, 9) and other cell types (7,
10); however, the possibility that there is a voltage-dependent step
at the level of either G protein or PLC activation (8–10) cannot be
fully excluded.
The potentiation of CCICR and vasoconstriction by ATP de-
scribed in this article might have a significant role in physiological
and pathophysiological conditions presenting myocyte depolariza-
tion and increase of external ATP concentration. ATP is coreleased
with NE from sympathetic terminals and also from cells (erythro-
cytes and platelets) that are damaged during vascular injury (11–
13). In this regard, a most representative condition is the delayed
cerebral vasoconstriction characteristic of patients with subarach-
noid hemorrhage (SAH). Although the cause of this type of
cerebral vasospasm is likely of multiple origin, there is a wealth of
data suggesting that ATP released from blood clots (erythrocytes
and platelets) might have an important contribution (13, 38, 39).
We have shown here that, at concentrations that cannot evoke
contraction, ATP potentiates both CCICR and the vasoconstriction
induced by depolarization with high K. It has been shown that, in
experimental SAH, cerebral arterial myocytes are depolarized (40,
41) therefore, it is possible that the conjunction of membrane
depolarization and ATP release (12, 13) (even at low concentra-
tions) leads to cerebral vasospasm. The fact that organic Ca2
channel antagonists inhibit not only extracellular Ca2 influx but
also CCICR (6) would explain the beneficial effect of these drugs
in the prevention or treatment of ischemia secondary to SAH (42).
In conclusion, our data support the view that L-type Ca2 channels
in basilar VSMCs are not only mediators of Ca2 influx, but they
also have a metabotropic action, leading to Ca2 release from the
SR. This metabotropic effect of Ca2 channels, markedly potenti-
ated by even low concentration of ATP acting directly on Ca2
channels, could contribute to vascular pathophysiology.
Fig. 4. CCICR-induced contraction in intact arterial rings and
potentiation by external ATP. (A) Contractive response of a
basilar arterial ring exposed to 70 mM K in the absence of
extracellular Ca2 (Ca2-free external solution plus 500 M
EGTA added). (B) FPL (1 M)-induced contraction in the ab-
sence of extracellular Ca2 plus 500 M EGTA added. (C)
Suppression of contraction evoked with FPL (1 M) by appli-
cation of an inhibitor of PLC (U73122, 2 M). (Inset) The Ca2
current (generated by depolarization to 20 mV from 70
mV) is not significantly affected by the presence of U73122 (10
M). (D Left) Low concentrations of ATP (1 M) markedly
induced a potentiation of vasoconstriction induced by 40 mM
K in the presence of the ATP-receptor antagonist suramin (25
M). (D Right) Comparison of vasoconstriction in arteries
exposed to 40 mM K and ATP (1 M, filled bars; 10 M, open
bars) and suramin. (E Left) In 0Ca solutions, ATP (10 M)
markedly increased isometric force induced by FPL (10 M).
During the time indicated by the asterisks, intracellular stores
were refilled by application of 40 mM K solution in the
presence of Ca2. (E Right) Summary of ATP (1–10 M) and
nifedipine (0.5–2 M) effects on isometric force developed in
arterial rings exposed to FPL (1–20 M). In all cases, the 0Ca
solution contained 200–500 M EGTA. *, P  0.05. The num-
ber of arterial rings studied is indicated in parentheses.
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Materials and Methods
Preparation of Dispersed Basilar Myocytes. Isolated rat basilar arte-
rial myocytes were obtained from anesthetized Wistar rats (250–
300 g). Basilar arteries were dissected from the brain, cut into
pieces, and incubated at 4°C for 12–14 h in Hanks’ solution
containing 1.3 mgml papain, 1.2 mgml collagenase, 40 IUml
elastase, and 0.75 mgml BSA. Cells were mechanically dispersed
and plated on coverslips. Myocytes were easily distinguished by
their size and typical elongated shape or by their immunoreactivity
to -actin (6).
Cytosolic Ca2Measurements and Patch-Clamp Recordings. Cytosolic
[Ca2] was estimated in intact and dialyzed cells. In the first case,
myocytes were incubated in Hanks’ solution with 1 M Fura 2-AM
added for 15 min at room temperature. In dialyzed cells, Fura 2
potassium salt (50M) was added to the patch pipette solution. For
the experiments, a coverslip with cells was placed on a recording
chamber mounted on the stage of an inverted microscope (Axiovert
35, Zeiss) equipped with epifluorescence and photometry. Alter-
nating excitation wavelengths of 340 and 380 nm were used, and
background fluorescence was subtracted before obtaining the
F340F380 ratio. Calibration of Ca2 signals was done in vitro as
described in ref. 43. Voltage- and current-clamp recordings were
performed by using the whole-cell configuration of the patch-clamp
technique (6, 43). When cytosolic [Ca2] and membrane holding
potential or current were recorded simultaneously, the signals were
digitized at a sampling interval of 500 ms and filtered at 3 KHz.
Ca2 currents were digitized by using a sample interval of 50s. All
the experiments were performed at room temperature (22°C).
Solutions. The composition of Hanks’ solution was 125 mM NaCl,
5.36 mM KCl, 5 mM NaHCO3, 0.34 mM Na2HPO4, 0.44 mM
KH2PO4, 10 mM glucose, 1.45 mM sucrose, and 10 mM Hepes, pH
7.4. The recording chamber was continuously superfused with a
standard external solution with 140 mM NaCl, 2.7 mM KCl, 2.5 mM
CaCl2, 1 mM MgCl2, and 10 mM Hepes, pH 7.4. Unless otherwise
noted, all the drugs used were added to this solution at the indicated
concentration. The 70 mM K solution was obtained by replacing
70 mM of NaCl with KCl. The 0Ca solution was obtained by
substituting Mg2 for Ca2 and with 2 mM EGTA added. Cytosolic
Ca2 measurements and patch-clamp recordings were done by
dialyzing the cells with a standard internal solution containing 83
mM potassium glutamate, 47 mM KCl, 1 mM MgCl2, 10 mM
Hepes, 4 mM ATP-Mg, and 50 M Fura 2-potassium salt, pH 7.2.
To record whole-cell Ca2 currents, the solutions used were as
follows: external (140 mM NaCl, 2.7 mM KCl, 10 mM BaCl2, and
10 mM Hepes, pH 7.4); and internal (100 mM CsCl, 30 mM CsF,
2 mM MgCl2, 4 mM ATP-Mg, 10 mM EGTA, and 10 mM Hepes,
pH 7.2).
Measurement of Contractility in Arterial Rings. Basilar arteries were
cleaned of connective tissue, cut in rings (2 mm) and mounted on
a small-vessel myograph (JP Trading, Aarhus, Denmark) to mea-
sure isometric tension connected to a digital recorder (Myodataq-
2.01, Myodata-2.02 Multi Myograph System). The rings were
placed on a chamber filled with the standard external solution (10
mM glucose added) and bubbled with 95% O2 and 5% CO2 at pH
7.4. Before the experiments, the segments were subjected to an
optimal tension (90% of tension equivalent to an intramural
pressure of 100 mm Hg) and stabilized for at least 30 min. For
Ca2-free solution, CaCl2 was omitted, and 200–500 M EGTA
was added. After the equilibration period, we discarded arterial
rings that developed a tension of1 mN in response to KCl (40–70
K). Experiments in the absence of Ca2 were done after incubat-
ing arterial rings in Ca2-free solution for 15 min and washing the
external solution at least four times. All the drugs used were added
directly to the chamber while vessel tension was monitored. Ex-
periments were performed at 37°C.
Statistical Analysis. Data are expressed as mean  SE, and the
statistical significance was estimated by using the Student t test.
Values of P  0.05 were considered significant.
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